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INTRODUCTION
Even though the pivotal article stating the theoreti-cal basis for a biopharmaceutics drug classification (1) was published almost 20 years ago, the extension 
of BCS-based biowaiver decisions to drugs belonging to 
BCS classes other than those showing high solubility and 
high permeability has not yet reached a consensus among 
regulators, industrial scientists, and academics. Also, within 
some jurisdictions, BCS principles have not yet been incor-
porated into legal frameworks and thus have not been 
used to allow science- and risk-based regulatory flexibility.
This report provides a brief description of the 
presentations from the International Workshop on 
Implementation of Biowaivers based on the BCS in Buenos 
Aires, Argentina, that took place on March 5–6, 2015. 
The meeting was cosponsored by National University 
of La Plata, Confederación Farmacéutica Argentina, 
International Pharmaceutical Federation (FIP), and the 
American Association of Pharmaceutical Scientists (AAPS). 
The main objectives of the meeting were to describe the 
state of the art with respect to in vitro and in silico tools 
to support waiving in vivo bioequivalence studies and 
to foster discussion about implementing BCS-based 
biowaiver decisions to support generic drug registration 
in South America. Two hundred and fifteen scientists from 
universities, the pharmaceutical industry, and regulatory 
authorities took part in this meeting. 
THE PRESENTATIONS
The Chairs of the meeting, Prof. Pablo Quiroga, Dr. 
Rodrigo Cristofoletti, Prof. Jennifer Dressman, and the FIP 
CEO, Dr. Luc Besancon, opened the meeting and welcomed 
the audience and speakers.
In Plenary Session 1, Dr. Vinod Shah presented the 
scientific principles of BCS and how the Food and Drug 
Administration (FDA) incorporated them into its regulatory 
framework, firstly as an important tool for setting the 
requirements for supporting post-approval changes and, 
subsequently, for supporting new and abbreviated drug 
applications. Prof. Dr. Jennifer Dressman spoke about 
methods to characterize drug solubility according to BCS 
and pointed out some pitfalls found in the description 
of drug solubility assessment using shake-flask methods 
extracted from a CRO website. She also discussed the dose 
definition for drug solubility classification purposes. Using 
different dose definitions, “highest single therapeutic 
dose” or “highest dosage strength,” might lead to BCS 
class migration, such as in the cases of metoclopramide 
and prednisone (2). Prof. Dr. Peter Langguth reviewed 
currently available in vitro (e.g., Caco-2 and MDCK cells 
monolayers), in situ (e.g., rat intestinal perfusion model), 
and in vivo (e.g., human intestinal perfusion model, 
absolute bioavailability, and mass balance) methods for 
assessing drug intestinal permeability. He cautioned about 
potential excipient effects on gastrointestinal motility 
as well as the possibility of them acting as competitors 
for some uptake and influx transporters, affecting drug 
absorption in a way that is not possible to anticipate by in 
vitro dissolution testing. This topic was further addressed 
by Prof. Dr. James Polli, who discussed the risks of 
extending BCS-based biowaiver decisions to BCS Class 
3 drugs, focusing on potential excipient effects on drug 
absorption. He presented some recent unpublished data 
from his research team, showing that even though some 
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common excipients did not seem to affect permeability 
of cimetidine and acyclovir, which are P-glycoprotein 
substrates, they can impact in vivo dissolution, as was 
observed after administering formulations containing high 
amounts of HPMC and magnesium stearate. However, as 
long as in vitro experimental conditions are biorelevant, 
excipient effects such as the latter ones described could 
be anticipated. He also discussed that in vitro studies 
might be better than traditional pharmacokinetic studies 
for assessing bioequivalence between test and reference 
formulations, highlighting the following advantages: (1) 
reduced costs; (2) in vitro dissolution tests directly assess 
product performance; (3) ethical considerations; and (4) 
elimination of problems arising from inconclusive in vivo 
bioequivalence studies showing high type II error. Prof. 
Dressman also spoke about FIP Biowaiver Monographs, 
a project that was and is mainly intended to publish 
Biowaiver Monographs of drug substances that appear 
on the WHO List of Essential Medicines and, occasionally, 
other drug substances finding very common use. The FIP 
Biowaiver Monograph reports all relevant data found in 
the open scientific literature and also reviews critically the 
reliability of these published scientific data and identifies 
gaps. So far, 43 monographs have been published, and 
many others are ongoing. Also, Prof. Dressman indicated 
that three of the ten most accessed articles in J. Pharm. Sci. 
in 2014 were FIP Biowaiver Monographs, highlighting the 
worldwide relevance of the project. Prof. Dr. Leslie Benet 
was the last speaker of the first session. His presentation was 
prerecorded since he had already accepted an invitation 
to attend another meeting on the same date. Prof. Benet 
explained that Biopharmaceutics Drug Disposition and 
Classification System (BDDCS) is a modification of BCS 
developed after identifying that there was a very good 
correlation between extent of drug absorption and extent 
of metabolism. He pointed out that there is no conflict 
between BCS and BDDCS but simply that each system 
has a different purpose and utilizes a different measure of 
intestinal permeability. While the objective of the BCS is to 
predict in vivo performance of drug products, BDDCS was 
proposed to serve as a basis for predicting the importance 
of transporters in determining drug bioavailability and 
disposition. In his opinion, any difference between BCS 
and BDDCS is not due to the systems per se, but to the 
ambiguous definition of permeability stated by FDA, which 
defines a kinetic parameter, intestinal permeability, in terms 
of a thermodynamic measure, extent of drug absorption.
In Plenary Session 2, Dr. Vinod Shah reviewed 
metrics currently available to compare dissolution profiles. 
These can be categorized as model-independent or 
model-dependent methods. He highlighted that the f2 
metric, initially proposed by Moore and Flanner (3) based 
on mean-squared difference and further statistically 
developed through mathematical scaling by Shah and 
coworkers (4, 5), ended up being the simplest and broadly 
accepted mathematical approach to compare dissolution 
profiles based on the assumption that an average 
difference of up to 10% between two dissolution profiles 
is not significant. Dr. Shah also emphasized that since 
the f2 factor is calculated using mean percentage of drug 
dissolved at each sampling time point, high variability may 
bias the mean estimates. This can be overcome by using 
bootstrap methods (4) to build 90% confidence intervals. 
Nevertheless, standardization of simulation techniques 
in this field is still lacking. Prof. Dr. Bertil Abrahamson 
presented some experimental examples and suggestions 
of how clinical relevance of dissolution testing can be 
achieved in the context of Quality by Design (QbD), 
emphasizing that in vitro dissolution testing together 
with BCS considerations could provide a key link between 
manufacturing/product design variables and clinical 
safety/efficacy in QbD. Also, Prof. Dr. Abrahamson pointed 
out that IVIVR and physiologically based pharmacokinetic 
models (PBPK) can be useful tools to build “safe spaces” 
aiming to achieve regulatory flexibility, which in turn, may 
facilitate continuous improvement of both drug product 
and manufacturing process (6). Prof. Pablo Quiroga used 
the equation for calculating risk priority number (RPN) in 
Failure Mode and Effects Analysis (FMEA), first suggested by 
Kubinga and coworkers (7) as a useful tool for supporting 
biowaivers to assess the risks of extending BCS-based 
biowaiver decisions to BCS Class 2 drugs. He focused on 
the element of the risk equation related to the capacity of 
detection and reviewed the literature to identify whether 
the current set of experimental conditions recommended 
by BCS guidelines could anticipate the bioequivalence 
outcome for poorly soluble and highly absorbed drugs. 
Some issues related to the dynamic acidification of the 
thin diffusion layer in response to ionization of some weak 
acids, which in turn can affect the dissolution of the drug 
product itself, which do not seem to be captured by the 
high buffer capacity dissolution media were raised (8). This 
led to the conclusion that the current capacity of detection 
would need to be improved to allow a biowaiver for BCS 
Class 2 drugs. Prof. Peter Langguth was the last speaker 
of the afternoon session and spoke about predicting food 
effects on the oral drug product performance using BCS. He 
presented several examples, highlighting an influence of 
food on intestinal drug metabolism and uptake and efflux 
transport system and a negative food effect on BCS Class 
3 drugs, mainly affecting drug substance (e.g., intestinal 
dilution) or drug product (e.g., increasing viscosity of 
dissolution fluid).
Plenary Session 3 was dedicated to the utilization of 
BCS principles in the regulatory environment. Six speakers 
presented a worldwide overview about BCS-based 
biowaiver requirements within different jurisdictions. Dr. 
Mehul Mehta presented the current decision tree that 
FDA has been using to evaluate BCS-based biowaiver 
submissions. He said that the Advisory BCS Committee 
has reviewed 63 submitted applications so far, and 67% of 
them were granted BCS-based biowaiver approval since 
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they belonged to BCS Class 1. New drug and abbreviated 
drug applications accounted for 48% and 52% of the 
submissions, respectively. Dr. Mehta also emphasized that 
FDA has been reviewing its BCS guidance, and they will 
move toward accepting biowaiver applications for BCS 
Class 3 drugs in the future, but without changing the dose 
definition for solubility classification purposes. Prof. Dr. 
Dressman reviewed WHO, EMA, and FDA BCS guidances, 
pointing out the main differences among them. She 
discussed the European criteria that allow biowaivers for 
BCS Class 3 drugs. Although on one hand, the procedure 
is scientifically robust, on the other hand, it is unclear 
how regulatory authorities will handle the “quantitatively 
similar” criterion given that quantities of excipients in the 
reference formulation are not disclosed, except in some 
cases, in the Netherlands. Even though generic companies 
can use reverse engineering tools to unveil reference 
formulations, she pointed out that regulators will have 
to compare the product composition with the registered 
formulation. Some legal issues related to confidentiality 
may arise. Dr. Yanina Rodriguez spoke about the legal 
framework for generic drug registration in Argentina. She 
provided the audience with an overview of the possibilities 
of biowaivers accepted by the Administración Nacional de 
Medicamentos, Alimentos y Tecnología Médica (ANMAT), 
emphasizing biowaivers for lower dosage strengths in case 
of proportionality of the formulations and based on BCS 
principles, for some listed BCS Classes 1 and 3 drugs. Dr. 
Rodriguez mentioned that ANMAT performs some in vitro 
dissolution tests to assess whether the reference listed 
drugs will fulfill at least the rapid dissolution criterion before 
deciding to add a drug to the list. Dr. Gustavo Mendes 
Lima Santos spoke about the Brazilian legal framework 
for biowaivers, Resolução RDC n. 37/11. He presented the 
three possibilities of biowaiver currently available in Brazil: 
(1) self-evident bioequivalence; (2) lower dosage strengths; 
and (3) BCS based. Given that at the time of publication of 
the Brazilian BCS guideline, it was identified that the views 
about BCS principles were not adequately harmonized 
through academics, industrial scientists, and regulators, 
the Agência Nacional de Vigilância Sanitária (ANVISA) 
decided to start off with a stepwise approach, elaborating 
a dynamic list with some candidates for BCS-based 
biowaiver decisions. Dr. Santos explained that ANVISA and 
sponsors share responsibilities in this field. While ANVISA 
is responsible for the classification of the extent of drug 
absorbed, risk assessment in terms of drug therapeutic 
index, and evaluation of whether there is evidence of 
non-BE results not detected by in vitro dissolution tests 
for the selected drugs in its internal database (SINEB), 
sponsors should submit solubility and in vitro dissolution 
results according to the BCS guideline. He also said that 
the Brazilian BCS guideline is currently under revision, and 
an update is expected by next year. Dr. Alexis Aceituno 
presented the Chilean legal framework for bioequivalence 
and biowaiver. He said that initially, the Instituto de Salud 
Publica (ISP) required in vivo BE studies only for two drugs, 
but currently, the number of drugs has increased to more 
than 150. He highlighted that BCS-based biowaivers can be 
granted for some BCS Classes 1, 2, and 3 in a case-by-case 
approach. The last speaker of this session was Dr. Mariana 
Pagano, who represented the Ministry of Health of Uruguay. 
She discussed the main points of the legal framework 
within her jurisdiction related to interchangeability of 
generics, mentioning that BCS principles had already been 
incorporated into the Uruguayan guidelines. At the end of 
this session, it was possible to identify some divergences 
among the BCS guidelines issued by South American 
regulatory authorities and also among FDA, EMA, and WHO. 
A harmonization of such criteria would facilitate future 
mutual recognition and information exchange within the 
regulatory environment. Thus, any attempt to harmonize 
dose definition for solubility classification purposes, 
cutoff value for classifying the extent of drug absorption, 
experimental in vitro dissolution conditions (e.g., for 50 or 
75 rpm for paddle apparatus?), and BCS-based biowaiver 
extensions beyond Class 1 drugs is very welcome. 
Plenary Session 4 was dedicated to in silico methods. 
Prof. Dr. Bertil Abrahamson spoke about the Oral 
Biopharmaceutics Tools (OrBiTo) Project showing the four 
Work Packages (9–11). OrBiTo is a partnership among 
pharmaceutical companies, universities, and commercial 
PBPK software development companies, whose main 
goal is to improve tools to predict the performance of 
orally administered drugs. Prof. Abrahamson discussed 
the current situation of the project and the main issues 
(e.g., lack of scientific understanding in areas like intestinal 
precipitation, gastrointestinal hydrolysis, and differences 
in regional permeability). He also highlighted that 
conventional quality control dissolution methods often fail 
to predict in vivo outcomes, and sometimes they are over-
discriminative to variables that are not relevant in vivo. 
Prof. Dr. Alan Telavi discussed the importance of having in 
silico models to predict drug intestinal permeability. Prof. 
Dr. Telavi spoke about some efforts aimed at the integrated 
prediction of several significant molecular properties 
in the field of drug discovery, such as pharmacological 
activity, aqueous solubility, human intestinal permeability, 
and affinity to P-glycoprotein. Dr. Rodrigo Cristofoletti 
discussed the importance of taking PK/PD relationships 
into consideration to set clinically relevant limits for in vivo 
bioequivalence studies (12), according to the scientific 
background provided by the Biopharmaceutics Risk 
Assessment Roadmap (BIORAM) (13). He also emphasized 
the importance of in silico tools like PBPK/PD models to 
explore “what if” scenarios, and sensitivity analysis that may 
be useful to identify the most relevant variables, which in 
turn should be more thoroughly investigated using in vitro 
or in vivo methods. Dr. Cristofoletti concluded that such 
approaches may help in building clinically relevant “safe 
spaces” that can facilitate continuous improvement of the 
formulation based on science and risk-based regulatory 
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flexibility. Prof. Dressman returned to the stage one more 
time to speak about using in vitro results to predict in vivo 
outcomes with PBPK models as convolution techniques. 
She highlighted the importance of using biorelevant 
experimental conditions when trying to predict in vivo 
dissolution. Prof. Dr. Dressman also provided the audience 
with some successful examples of in vitro–in silico–in vivo 
extrapolation (IV–IS–IV–E) for poorly soluble drugs like 
aprepitant and nifedipine (14, 15). 
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